- HK$52.02bn
- HK$171.29bn
- CNY575.17bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.88 | ||
| PEG Ratio (f) | 1.54 | ||
| EPS Growth (f) | 3.99% | ||
| Dividend Yield (f) | 5.29% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.52 | ||
| Price to Tang. Book | 0.57 | ||
| Price to Free Cashflow | 1.93 | ||
| Price to Sales | 0.08 | ||
| EV to EBITDA | 7.22 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.35% | ||
| Return on Equity | 8.58% | ||
| Operating Margin | 2.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 521,051.24 | 552,147.55 | 596,569.57 | 584,507.93 | 575,167.88 | 576,643.97 | 593,543.37 | 4.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +12.29 | +4.47 | +1.86 | -10.27 | -3.39 | -4.76 | +5.34 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sinopharm Group Co Ltd is a China-based company principally engaged in the wholesale and retail of pharmaceutical and healthcare products and medical devices. The Company operates its business through four segments. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services to domestic and foreign pharmaceutical and health product manufacturers and other suppliers. The Device Distribution segment distributes medical devices to customers. The Pharmaceutical Retail Business segment owns a network of retail pharmacies that are directly operated or franchised. The Other Business segment is engaged in the manufacture and sale of pharmaceuticals, chemical reagents and laboratory supplies.
Directors
- Wanyong Lian PRE (55)
- Qiyu Chen NVC (54)
- Yijian Wu VPR (55)
- Maisong Cai VPR (56)
- Yang Li VPR (47)
- Xiaojuan Li CFO (49)
- Yuqing Chen NED (50)
- Binghua Yang EDR (46)
- Bin Jin NEC (53)
- Yue Ma NED (44)
- Ying Li NED (52)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 8th, 2003
- Public Since
- September 23rd, 2009
- No. of Employees
- 90,447
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 3,120,656,191

- Address
- Sinopharm Plaza, No. 1001 Zhongshan Road, SHANGHAI, 200023
- Web
- https://www.sinopharmgroup.com.cn/
- Phone
- +86 2123052666
- Auditors
- Confucius International CPA Limited
Latest News for 1099
Upcoming Events for 1099
Full Year 2026 Sinopharm Group Co Ltd Earnings Release
Q1 2027 Sinopharm Group Co Ltd Earnings Release
Similar to 1099
160 Health International
Stock Exchange of Hong Kong Limited
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio-Tech JS
Stock Exchange of Hong Kong Limited
AIM Vaccine
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 13:19 UTC, shares in Sinopharm are trading at HK$16.67. This share price information is delayed by 15 minutes.
Shares in Sinopharm last closed at HK$16.67 and the price had moved by -22.03% over the past 365 days. In terms of relative price strength the Sinopharm share price has underperformed the FTSE Developed Asia Pacific Index by -38.79% over the past year.
The overall consensus recommendation for Sinopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Sinopharm dividend yield is 5.01% based on the trailing twelve month period.
Last year, Sinopharm paid a total dividend of CNY0.71, and it currently has a trailing dividend yield of 5.01%. We do not have any data on when Sinopharm is to next pay dividends.
We do not have data on when Sinopharm is to next pay dividends. The historic dividend yield on Sinopharm shares is currently 5.01%.
To buy shares in Sinopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$16.67, shares in Sinopharm had a market capitalisation of HK$52.02bn.
Here are the trading details for Sinopharm:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1099
Based on an overall assessment of its quality, value and momentum Sinopharm is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sinopharm is HK$20.62. That is 23.67% above the last closing price of HK$16.67.
Analysts covering Sinopharm currently have a consensus Earnings Per Share (EPS) forecast of CNY2.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinopharm. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +2.08%.
As of the last closing price of HK$16.67, shares in Sinopharm were trading -6.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinopharm PE ratio based on its reported earnings over the past 12 months is 5.88. The shares last closed at HK$16.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinopharm's management team is headed by:
- Wanyong Lian - PRE
- Qiyu Chen - NVC
- Yijian Wu - VPR
- Maisong Cai - VPR
- Yang Li - VPR
- Xiaojuan Li - CFO
- Yuqing Chen - NED
- Binghua Yang - EDR
- Bin Jin - NEC
- Yue Ma - NED
- Ying Li - NED





